They may also prescribe over-the-counter medication such as loperamide and bismuth subsalicylate
Second, obese patients, with or without comorbidities, as an adjunct to diet and exercise
Here is a quick reference for researchers: Note: Amounts above ~150 mcg do not appear to produce proportionally greater GH output in research models, likely due to GHRH receptor saturation
FDA-Noted Concerns: Increased heart rate Systemic vasodilatory reactions Limited clinical safety data Immunogenicity risk (antibody formation) Reported Side Effects: Injection site reactions (redness, swelling, itching) Headache Flushing Dizziness Nausea Water retention Serious Concerns: Potential for glucose metabolism disruption Theoretical cancer risk (GH/IGF-1 promote cell proliferation) Long-term safety unknown Regulatory Status United States: CJC-1295 is not FDA approved for any indication
J Clin Invest 89 : 19081913 Ethics declarations Competing interests The authors declare no competing financial interests
Cardiovascular safety of albiglutide in the harmony programme: a meta-analysis